PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat bloodin vitro-Reference-Cited by-同舟云学术

PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat bloodin vitro

Published:1993-03 Issue:S1 Volume:39 Page:C99-C101
ISSN:0065-4299
Container-title:Agents and Actions
language:en
Short-container-title:Agents and Actions

Author:

Dong Mi K.,Gilbertsen Richard B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Toxicology,Pharmacology,Immunology

Link

http://link.springer.com/content/pdf/10.1007/BF01972733.pdf

Reference8 articles.

1. J. C. Sircar, C. R. Kostlan, R. B. Gilbertsen, M. K. Dong and W. A. Cetenko,Pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase (PNP) inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrolo[3,2-d]pyrimidin-4-one (CI-972). InPurine and Pyrimidine Metabolism in Man VII (Eds. R. A. Harkness, G. B. Elion and N. Zöllner), Part A, pp. 45–48, Plenum, New York 1991.

2. S. E. Ealick, Y. S. Babu, C. E. Bugg, M. D. Erion, W. C. Guida, J. A. Montgomery and J. A. Secrist III,Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors, Proc. Natl. Acad. Sci. USA88, 11540–11544 (1991).

3. R. B. Gilbertsen, M. K. Dong, L. M. Kossarek, J. C. Sircar, C. R. Kostlan and M. C. Conroy,Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972, Biochem. Biophys. Res. Commun.178, 1351–1358 (1991).

4. R. B. Gilbertsen, M. K. Dong, D. J. Wilburn, L. M. Kossarek, J. C. Sircar, C. R. Kostlan and M. C. Conroy,Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor. InPurine and Pyrimidine Metabolism in Man VII (Eds. R. A. Harkness, G. B. Elion and N. Zöllner), Part A, pp. 41–44, Plenum, New York 1991.

5. R. B. Gilbertsen, U. Josyula, J. C. Sircar, M. K. Dong, W. Wu, D. J. Wilburn and M. C. Conroy,Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955, Biochem. Pharm.44, 996–999 (1992).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The transition to magic bullets – transition state analogue drug design;MedChemComm;2018

2. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes—A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies;International Immunopharmacology;2010-07

3. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777;International Immunopharmacology;2003-06

4. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent;International Immunopharmacology;2001-06

5. Purine nucleoside phosphorylases: properties, functions, and clinical aspects;Pharmacology & Therapeutics;2000-12